SHL Medical (hereinafter referred to as "SHL") has revealed plans for a new 
manufacturing site in the US, in response to the growing market demand for its 
autoinjector product portfolio. The decision stems from SHL's strategic 
assessments in extending its production to North America.

Photo - https://mma.prnewswire.com/media/1858961/SHL_Medical_SC.jpg

The new US site will be located in North Charleston, South Carolina, and will 
boast approximately 25,000 m(2) (270,000 ft(2)). With initial investments of 
US$ 90 million, SHL is expected to create an estimate of 165 local employment 
opportunities. Operations are expected to launch by 2024. 

The South Carolina site will be an advanced facility with medical device 
injection molding and fully automated assembly capabilities. Together with 
SHL's current final assembly, labeling, and packaging operations in Deerfield 
Beach, Florida, the expanded manufacturing capabilities in the US will further 
fortify SHL's offerings in delivering comprehensive services to its partners.

In 2019, SHL developed a long-term strategy in response to the growing 
autoinjector demand and to meet future manufacturing needs. The announcement of 
the new US operation aligns with the company's ongoing expansion, including a 
new Swiss site already being announced ( 
https://c212.net/c/link/?t=0&l=en&o=3593771-1&h=1810659832&u=https%3A%2F%2Fwww.shl-medical.com%2Fshl-medical-reveals-plans-to-set-up-manufacturing-site-in-zug-switzerland%2F&a=a+new+Swiss+site+already+being+announced 
). The new production site in the US, which is to be realized preferentially 
and accelerated, will offer fully automated production facilities and a 
flexible supply chain with reduced distance to main markets.

Chairman and CEO Ulrich Faessler comments: "Demand for SHL's products has 
increased significantly. Therefore, we are speeding up our plans for a new 
plant in the US. Similar to our upcoming European site in Zug, Switzerland, the 
US site will be a state-of-the-art, fully automated site. This expansion 
signifies SHL's pledge to our advanced manufacturing strategy that will support 
our sustainability goals; and, at the same time, risk-mitigate supply chain 
disturbances through closer production with our customers, in light of various 
global events from the past two years. This further supports our customers with 
one-stop-shop capabilities, providing high-quality drug delivery systems to the 
end-users – the patients."

Media Contact 
Rylie Geraci  
BCW Global 
rylie.geraci@bcw-global.com

SOURCE: SHL Medical